Status:
UNKNOWN
A Study of Chronic Hepatitis C Patients Treated With SOF/VEL/VOX
Lead Sponsor:
Cerrahpasa Medical Faculty Foundation
Conditions:
Hepatitis C
Eligibility:
All Genders
18+ years
Brief Summary
This is a retrospective, non-interventional study. Investigators from infectious diseases and gastroenterology departments will participate this study. Patients data will be collected from hospital m...
Detailed Description
Pangenotypic Sofosbuvir/Velpatasvir/Voxilaprevir for 8-12 weeks has been shown highly effective, safe, and well-tolerated in treating patients with chronic HCV infection in clinical trial settings, ho...
Eligibility Criteria
Inclusion
- Patients diagnosed as chronic hepatitis C and aged 18 and older
- Patients received SOF/VEL/VOX treatment
Exclusion
- Decompensated cirrhotic HCV patients
- Having HCC
- eGFR\<30 ml/min
Key Trial Info
Start Date :
February 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2023
Estimated Enrollment :
450 Patients enrolled
Trial Details
Trial ID
NCT06010524
Start Date
February 1 2023
End Date
December 31 2023
Last Update
August 29 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cerrahpasa Medical Faculty
Istanbul, Turkey (Türkiye)